SMS Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

SMS Pharmaceuticals has received revision in credit ratings from CARE Ratings as under:

Long term bank facilities (Rs 350.87 crore) - CARE A; Positive (reaffirmed, outlook revised from Stable)

Short term bank facilities (Rs 52.83 crore) - CARE A1 (upgraded from CARE A2+)

Powered by Capital Market - Live News

This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence. The product had previously been withdrawn over concerns related to the formation of NDMA, a potential carcinogenic impurity.

According to the company, the approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.

The company?s consolidated net profit jumped 79.5% to Rs 25.31 crore on 23.2% increase in revenue from operations to Rs 242.43 crore in Q2 FY26 over Q2 FY25.

Powered by Capital Market - Live News

SMS Pharmaceuticals announced that the US Food and Drug Administration has approved its associate company VKT Pharma's reformulated Ranitidine tablets in 150mg and 300mg strengths. This approval marks the re-entry of this important acid-reducing medication into the US market after a five-year absence.

The approval by the US FDA comes after extensive safety testing and manufacturing improvements that address previous concerns regarding the formation of NDMA impurity. It is expected to increase patient access to this important medication for patients who rely on it for various health conditions.

Powered by Capital Market - Live News

Profit before tax (PBT) increased 74.21% YoY to Rs 34.04 crore in Q2 FY26.

Total expenses climbed 17.55% to Rs 209.82 crore in Q2 FY26, compared with Rs 178.50 crore in Q2 FY25. Cost of material consumed stood at Rs 106.56 crore (down 32.88% YoY), manufacturing expenses stood at Rs 25.73 crore (up 17.01% YoY), employee benefit expenses was at Rs 19.25 crore (up 7.42% YoY) and finance cost stood at Rs 5.73 crore (up 24.57% YoY) during the period under review.

On half yearly basis, the company?s consolidated net profit jumped 49.8% to Rs 45.80 crore on 21.4% increase in revenue from operations to Rs 438.48 crore in H1 FY26 over H1 FY25.

SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specializing in APIs and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag.

Powered by Capital Market - Live News